Antibody Neutralization of CXCL10in VivoIs Dependent on Binding to Free and Not Endothelial-bound Chemokine

Anti-CD3/Anti-CXCL10 Antibody Combination Therapy Induces a Persistent Remission of Type 1 Diabetes in Two Mouse Models

(2015) Stanley Lasch et al.   DIABETES

“Chemokine receptors as therapeutic targets: Why aren’t there more drugs?”

(2015) Roberto Solari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

 De novoisolation of antibodies with pH-dependent binding properties

(2015) Pauline Bonvin et al.   mAbs

CCR4 and its ligands: from bench to bedside

(2014) O. Yoshie et al.   INTERNATIONAL IMMUNOLOGY

CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis

(2014) Yaniv Zohar et al.   JOURNAL OF CLINICAL INVESTIGATION

Chemokines in Cancer Development and Progression and Their Potential as Targeting Molecules for Cancer Treatment

(2014) Naofumi Mukaida et al.   MEDIATORS OF INFLAMMATION

CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo

(2014) M. Rashighi et al.   Science Translational Medicine

Biased and G Protein-Independent Signaling of Chemokine Receptors

(2014) Anne Steen et al.   Frontiers in Immunology

Advances in understanding the pathogenesis of autoimmune disorders: focus on chemokines and lymphocyte trafficking

(2013) Iain Comerford et al.   BRITISH JOURNAL OF HAEMATOLOGY

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

(2013) Shahneen K. Sandhu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study

(2013) Lloyd Mayer et al.   GUT

Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data

(2013) Gerald J. Fetterly et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Interstitial Dendritic Cell Guidance by Haptotactic Chemokine Gradients

(2013) M. Weber et al.   SCIENCE

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

(2012) Kenneth J. Pienta et al.   INVESTIGATIONAL NEW DRUGS

Generalized Lévy walks and the role of chemokines in migration of effector CD8+ T cells

(2012) Tajie H. Harris et al.   NATURE

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

(2011) Michael Yellin et al.   ARTHRITIS AND RHEUMATISM

Chemokine oligomerization and interactions with receptors and glycosaminoglycans: The role of structural dynamics in function

(2011) C.L. Salanga et al.   EXPERIMENTAL CELL RESEARCH

Targeting chemokine receptors in chronic inflammatory diseases: An extensive review

(2011) Pim J. Koelink et al.   PHARMACOLOGY & THERAPEUTICS

CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation

(2010) Edith Hintermann et al.   JOURNAL OF AUTOIMMUNITY

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

T1145 A Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and Pharmacokinetic Study of MDX-1100, a Fully Human Anti-CXCL10 Monoclonal Antibody, in Healthy Subjects

(2008) Michael Yellin et al.   GASTROENTEROLOGY

Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria

(2008) G. S. V. Campanella et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA